From FDA labels and ClinicalTrials.gov

Do GLP-1s help prediabetes?

Last updated

If your prescriber prescribes one: the lowest self-pay GLP-1 prices now

  • Lowest compounded tirzepatide on a monthly plan, not FDA-approved

    Collective

    $69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest compounded semaglutide on a monthly plan, not FDA-approved

    Collective

    $59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest FDA-approved, starting dose

    LillyDirect (Eli Lilly)

    from $149/mo

  • Lowest FDA-approved injection, starting dose

    NovoCare (Novo Nordisk)

    $199/fill initially

No current GLP-1 label lists prediabetes as an approved use, so prescribing one for it would be off-label. SURMOUNT-1, three years (Tirzepatide): Among people with obesity and prediabetes, 1.3% on tirzepatide were diagnosed with type 2 diabetes by week 176 against 13.3% on placebo. After 17 weeks off treatment it was 2.4% against 13.7%. N Engl J Med, 2025 (pubmed.ncbi.nlm.nih.gov/39536238). ClinicalTrials.gov lists 36 trials of these medicines on it: 14 with posted results and 6 recruiting now.

Read from the registry and PubMed every day. The newest update here is Nov 5, 2026.

Published results

What the largest trials on prediabetes found

Each read in the paper's abstract on Nov 6, 2026. Trials differ in who took part and how long they ran.

SURMOUNT-1, three years

Tirzepatide · 1,032 people · Better than the comparison · Placebo-controlled randomized trial

Among people with obesity and prediabetes, 1.3% on tirzepatide were diagnosed with type 2 diabetes by week 176 against 13.3% on placebo. After 17 weeks off treatment it was 2.4% against 13.7%.

N Engl J Med, 2025 (pubmed.ncbi.nlm.nih.gov/39536238)

STEP 10

Semaglutide · 207 people · Better than the comparison · Placebo-controlled randomized trial

At week 52, 81% on semaglutide 2.4 mg had returned to normal blood sugar against 14% on placebo.

Lancet Diabetes Endocrinol, 2024 (pubmed.ncbi.nlm.nih.gov/39089293)

The registry

Trials on prediabetes, by medicine

A trial counts when the registry's conditions or title name this, and some study a related question, such as insulin sensitivity in people with the condition. A registered trial shows a question being asked, not that the answer is yes.

MedicineTrialsPosted resultsRecruiting
Semaglutide1325
Exenatide1070
Liraglutide1050
Mazdutide100
Orforglipron101
Tirzepatide100
Posted results

What trials on prediabetes reported

Latest phases and largest trials first. Each result is the first primary outcome as its sponsor posted it to the registry, which is not peer review.

TrialMedicinePhasePeopleResult
NCT01272219Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetesLiraglutidePhase 33,731Change From Baseline in Fasting Body Weight (percent change), Week 0, Week 56. Liraglutide 3.0 mg (56-Week): -7.98; Liraglutide Placebo (56-Week): -2.62.
RISE AdultRISE Adult Medication StudyLiraglutidePhase 3267Insulin Sensitivity, M/I (x 10-5 mmol/kg/min per pmol/L), 3-months after a medication washout. Metformin Alone: 3.53; Glargine Followed by Metformin: 3.38; Placebo: 3.63; Liraglutide + Metformin: 3.49.
STEP 10Research Study Looking at How Well Semaglutide Works in People Living With Obesity and PrediabetesSemaglutidePhase 3207Change in Body Weight (Percentage [%]) (Percentage (%) of body weight), From randomisation (week 0) to end of treatment (week 52). Semaglutide 2.4 mg: -14.4; Placebo: -2.7.
NCT01234649Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)LiraglutidePhase 3153Insulin Secretion-Sensitivity Index (IS-SI) (index), 84 weeks of treatment. Metformin XR Plus Liraglutide: 418.4; Metformin XR Plus Placebo: 333.
NCT01784965Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD.LiraglutidePhase 369Change in Weight Reported at 14 Weeks (kg), Baseline and 14 weeks. Placebo: -3.3; Liraglutide: -6.8.
NCT03101930Cardiovascular Effects of GLP-1 Receptor ActivationLiraglutidePhase 4329Change in Flow-mediated Dilation (Percentage), Baseline to 2 and 14 weeks, Baseline to 2 weeks (Placebo infusion). Liraglutide: 0.71; Sitagliptin: 2.06; Hypocaloric Diet: 1.24.
NCT01181986The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and PrediabetesExenatidePhase 476Reactive Hyperemia Index (RHI) (ratio), 0, 2, 4, 6 and 8 hours on Day 11 (Sub-study 1); 0 and 120 minutes on test Days 1, 2 & 3 (Sub-study 2). Exenatide (Subs-study 1): 1.90; Placebo (Sub-study 1): 1.79; Saline+Exenatide (Sub-study 2): 2.24; Saline+Placebo (Sub-study 2): 1.95; Exendin-9+Exenatide (Sub-study 2): 1.99.
NCT00546728The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-DiabetesExenatidePhase 450Change in Reactive Hyperemic Index Over the 3-month Treatment Period (ratio), Change from baseline to 3 months. Exenatide: 0.01; Metformin: -0.17.
PIO-EXEffect of Pioglitazone and Exenatide on Body Weight and Beta Cell FunctionExenatidePhase 443Effect of Pioglitazone, Exenatide and Combined Pioglitazone and Exenatide on Body Weight (kg), baseline and 6 months. PIOGLITAZONE: 5.5; EXENATIDE: 2.4; PIOGLITAZONE and EXNATIDE: 2.7.
NCT00456885The Effect of Exenatide on Weight and Hunger in Obese, Healthy WomenExenatidePhase 441Change in Weight (kilograms), 16 weeks after the beginning of each treatment. Exenatide: -2.49; Placebo: 0.43.
NCT02104739Effects of Antidiabetic Medications on the Postprandial State in PrediabetesExenatidePhase 421Monocyte NfkB Levels as Detected by Western Blotting (NfkB p65 arbitrary units), baseline. Exenatide: 62.79; Saxagliptin: 72.03; Placebo: 67.68; Exenatide Extended-release (ER): 84.19.
NCT05786521Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older AdultsSemaglutidePhase 420Lean Body Mass Change (g), Baseline to 20 weeks. Semaglutide and Lifestyle Intervention: -1730.6; Lifestyle Intervention: -421.
NCT01588418Acute Effect of Exenatide on Brain Glucose MetabolismExenatidePhase 415On ClinicalTrials.gov (clinicaltrials.gov)
NCT00775684Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell MassExenatideNot phased47Effect on Functional Beta-cell Mass as Determined by Change in ß-cell Secretory Capacity at 6 Months (μU/ml) (μU/ml), Baseline and 6 months, Acute Insulin Response (AIRmax)Baseline. Exenatide: 214; Sitagliptin: 149; Glimepiride: 133.
Recruiting now

Trials on prediabetes taking people now

The registry page names each site and who can enroll. Ask your clinician before joining one.

TrialMedicinePhaseExpected to finish
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity (clinicaltrials.gov/study/NCT07794579)OrforglipronPhase 3Sep 2030
Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes (clinicaltrials.gov/study/NCT05119179)SemaglutidePhase 4Oct 31, 2026
Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes (clinicaltrials.gov/study/NCT07254572)SemaglutidePhase 4Aug 1, 2029
Genetics of the Acute Response to Oral Semaglutide (clinicaltrials.gov/study/NCT05340868)SemaglutideNot phasedDec 31, 2025
A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes (clinicaltrials.gov/study/NCT07195994)SemaglutideNot phasedSep 2026
Prevention of Progression of Prediabetes, Obesity and CV Risk (clinicaltrials.gov/study/NCT06446531)SemaglutidePhase 1Jul 2027
From PubMed

Newest papers on GLP-1s and prediabetes

  • Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly. Diabetes Care 2026;49:XXXX-XXXX (pubmed.ncbi.nlm.nih.gov/42765971)

    Randomized trial · Diabetes Care · Sep 21, 2026 · Chen L et al.

  • Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly (pubmed.ncbi.nlm.nih.gov/41778920)

    Randomized trial · Diabetes Care · May 1, 2026 · Ganeshalingam AA et al. · cited by 2

  • Acute interleukin-1β antagonism decreases systemic inflammation, increases GLP-1 release, and modulates insulin secretion in individuals with prediabetes (pubmed.ncbi.nlm.nih.gov/41778408)

    Randomized trial · Am J Physiol Endocrinol Metab · Mar 4, 2026 · Fischer JS et al. · cited by 2

  • Effectiveness of GLP-1 RAs in Restoring Normoglycemia in Patients With Prediabetes: An Updated Systematic Review and Meta-Analysis (pubmed.ncbi.nlm.nih.gov/41398448)

    Meta-analysis · Diabetes Metab Res Rev · Jan 1, 2026 · Tsironikos GI et al. · cited by 1

  • Semaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and Obesity: The HISTORI Randomized Clinical Trial (pubmed.ncbi.nlm.nih.gov/40900607)

    Randomized trial · JAMA Psychiatry · Nov 1, 2025 · Ganeshalingam AA et al. · cited by 44

  • Tirzepatide and the 10-year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three-year SURMOUNT-1 trial (pubmed.ncbi.nlm.nih.gov/41017451)

    Randomized trial · Diabetes Obes Metab · Sep 29, 2025 · Hankosky ER et al. · cited by 15

Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.

Updated automatically

What changed in trials on prediabetes

  • TrialSemaglutide study now active, not recruiting (was not yet recruiting): A Retrospective Real-World Cohort Study (clinicaltrials.gov/study/NCT07781371)

Written from each source's own record as it changes. Every change on GLPcompare

Questions

GLP-1s and prediabetes: common questions

What did the largest trial on prediabetes find?

SURMOUNT-1, three years (Tirzepatide, 1,032 people): Among people with obesity and prediabetes, 1.3% on tirzepatide were diagnosed with type 2 diabetes by week 176 against 13.3% on placebo. After 17 weeks off treatment it was 2.4% against 13.7%.

Is any GLP-1 FDA approved for prediabetes?

Not in any current label we read. A prescriber can still use a medicine off-label, but insurance often limits coverage to approved uses, so ask your plan.

Which GLP-1 has been studied most for prediabetes?

Semaglutide, with 13 registered trials on it, then Exenatide and Liraglutide with 10 each. More trials do not mean better results: read what each posted.

Can I join a trial of a GLP-1 for prediabetes?

6 trials are recruiting on ClinicalTrials.gov now, listed on this page with their registry pages, which name each site and who can enroll.

Other conditions

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.